Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jan 24:14:1275753.
doi: 10.3389/fendo.2023.1275753. eCollection 2023.

Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis

Mei Wang  1 , Jiao Tong  1 , Qing Zhu  1 , Huaiyun Tang #  1 , Lisha Tang #  1
Affiliations
Meta-Analysis

Blood nesfatin-1 levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis

Mei Wang et al. Front Endocrinol (Lausanne). .

Abstract

Background: Previous studies have investigated the relationship between nesfatin-1 level and polycystic ovary syndrome (PCOS). However, these studies have produced conflicting results. Thus, in this meta-analysis, we aimed to clarify the association between blood nesfatin-1 levels and PCOS, and the ability of nesfatin-1 as a biomarker in PCOS.

Methods: Meta-analysis was performed using STATA 12.0 software. We computed standard mean difference (SMD) and 95% confidence interval (CI) regarding the comparison of blood nesfatin-1 in patients with PCOS and controls.

Results: The present meta-analysis showed no significant difference in blood nesfatin-1 level between patients with PCOS and controls with a random effects model (SMD = 0.03; 95%CI: -0.71, 0.77; I2 = 97.1%, p value for Q test < 0.001). Subgroup analysis for different ethnicities reported no significant difference in blood nesfatin-1 level between patients with PCOS and controls in both Caucasian and Asian populations. Subgroup analysis for different sample types reported no significant difference in serum nesfatin-1 level between patients with PCOS and controls. Subgroup studies reported no significant difference in blood nesfatin-1 level between PCOS and controls in both obese and non-obese populations.

Conclusion: In conclusion, there is no significant relationship between blood nesfatin-1 levels and PCOS.

Keywords: meta-analysis; nesfatin-1; polycystic ovary syndrome; serum; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the literature search and selection process.
Figure 2
Figure 2
Forest plot for comparison in blood nesfatin-1 level between patients with PCOS and controls. CI, confidence interval; PCOS, polycystic ovary syndrome; SMD, standard mean difference.
Figure 3
Figure 3
Subgroup analysis for comparison in blood nesfatin-1 level between patients with PCOS and controls with different ethnicities. CI, confidence interval; PCOS, polycystic ovary syndrome; SMD, standard mean difference.
Figure 4
Figure 4
Subgroup analysis for comparison in nesfatin-1 level detected by different sample types between patients with PCOS and controls. CI, confidence interval; PCOS, polycystic ovary syndrome; SMD, standard mean difference.
Figure 5
Figure 5
Subgroup analysis depending on presence and absence of obesity for comparison in nesfatin-1 level between patients with PCOS and controls. CI, confidence interval; PCOS, polycystic ovary syndrome; SMD, standard mean difference.
Figure 6
Figure 6
Sensitivity analysis for comparison in blood nesfatin-1 level between patients with PCOS and controls. PCOS, polycystic ovary syndrome.
Figure 7
Figure 7
Funnel plot for comparison in blood nesfatin-1 level between patients with PCOS and controls. PCOS, polycystic ovary syndrome.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gomez JMD, VanHise K, Stachenfeld N, Chan JL, Merz NB, Shufelt C. Subclinical cardiovascular disease and polycystic ovary syndrome. Fertil Steril (2022) 117(5):912–23. doi: 10.1016/j.fertnstert.2022.02.028 - DOI - PMC - PubMed
    1. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health (2018) 15(11):2589. doi: 10.3390/ijerph15112589 - DOI - PMC - PubMed
    1. ESHRE TR, Group A-SPCW . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril (2004) 81(1):19–25. doi: 10.1016/j.fertnstert.2003.10.004 - DOI - PubMed
    1. Witchel SF, Teede HJ, Peña AS. Curtailing PCOS. Pediatr Res (2020) 87(2):353–61. doi: 10.1038/s41390-019-0615-1 - DOI - PubMed
    1. Dapas M, Dunaif A. Deconstructing a syndrome: genomic insights into PCOS causal mechanisms and classification. Endocr Rev (2022) 43(6):927–65. doi: 10.1210/endrev/bnac001 - DOI - PMC - PubMed

Publication types